Novartis Targets Quick Launches For Zolgensma in Europe
Conditional Approval Finally Granted For SMA Gene Therapy
The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.
You may also be interested in...
Applications to market Roche’s spinal muscular atrophy drug have already been submitted in eight countries including the US, where a decision is due in August.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.
An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.